Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement
07 Abril 2009 - 4:00PM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in
compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the
independent audit report included in the Company�s Annual Report on
Form 10-K for the fiscal year ended December 31, 2008 contained an
unqualified audit opinion from its independent public accounting
firm, Ernst & Young LLP, which included a �going concern�
explanatory statement. This disclosure is required under NASDAQ
rules and does not represent any change to the Company�s Annual
Report on Form 10-K for the year ended December 31, 2008 which was
filed on March 31, 2009 with the Securities and Exchange
Commission.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer
therapeutics.
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Avalon Pharmaceuticals (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Avalon Pharmaceuticals, Inc.